Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Oral minoxidil effectively reduces hair shedding in women with chronic telogen effluvium.

Oral minoxidil significantly reduces hair shedding in women with chronic telogen effluvium.

This article updates Japanese guidelines for diagnosing and treating male and female-pattern hair loss, recommending specific drugs and therapies while advising against certain treatments for female-pattern hair loss.

This guideline outlines therapies for hidradenitis suppurativa/acne inversa, noting that oral tetracyclines, clindamycin, and surgical options are important for treatment, with adalimumab, secukinumab, and bimekizumab also approved.

This study found that topical minoxidil increases hair density more than placebo in both men and women with androgenetic alopecia, achieving about 21 additional hairs per cm² after 16 to 48 weeks, while oral and topical versions show similar efficacy but different side effects.

This study aims to compare the differences in adverse reactions and efficacy between topical and oral use of minoxidil for hair growth, with a focus on newer, lower-dose oral applications originally used for hypertension.

Low-dose oral minoxidil may be a promising alternative to topical minoxidil for hair loss.

In this survey, dermatologists in India reported preferring alcohol-free minoxidil combined with procapil and finasteride over traditional alcohol-based formulations for managing androgenetic alopecia, citing better tolerance and patient adherence.

This systematic review discusses various topical, oral, injectable, and non-pharmacological treatments for androgenetic alopecia, examining both current and emerging therapeutic options in addressing this common form of hair loss.

This review examines the roles and benefits of chitosan in cosmetics and oral hygiene, highlighting its potential in the cosmeceutical market, but it reports no new results.

This review discusses the pathophysiology of sleep disturbance in children with atopic dermatitis and highlights the need for further research on management strategies, but provides no new clinical results.

This study reviews the evolution and modifications of microneedle drug delivery systems, initially designed for percutaneous use, now expanded for targeting a variety of tissues and organs such as ocular, oral mucosal, and gastrointestinal, suggesting widespread future applicability.

This review discusses the historical development of platelet-rich fibrin from fibrin glue to platelet-enriched formulations and reports no new clinical results.

In this study, a genetic analysis identified a pathogenic variant in the ALOXE3 gene associated with non-bullous congenital ichthyosiform erythroderma, and the patient's response to antifungal treatment highlights the risk of cutaneous fungal infections.

This study provided insight into unexpected uses and abuse of oral contraceptive pills by Jordanian males, primarily for bodybuilding, as reported by community pharmacists.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

In this study, women with chronic telogen effluvium experienced reduced hair shedding after being treated with once daily oral minoxidil for 12 months, but facial hypertrichosis was a reported side effect, suggesting the need for further placebo-controlled research.

This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.

This study found that using very-low-dose oral minoxidil (0.25 mg/d) led to improvement or stabilization of hair parameters in 40% to 60% of men with androgenetic alopecia, although results were not statistically significant for the overall group.

This study found that combining oral isotretinoin with topical treatments was more effective than topical treatments alone for improving frontal fibrosing alopecia symptoms, despite some side effects.

This report describes nine women who were allergic to topical minoxidil but successfully tolerated low-dose oral minoxidil without significant adverse effects, suggesting it may be a viable alternative for those with similar allergies.

In this study, 60 mg/day of Cepharanthine significantly reduced the time to a negative COVID-19 test among de novo infected patients with good compliance, though 120 mg/day showed no such effect.

This preclinical study found that Mesenchymal Stem Cell-derived Conditioned Media formulations were safe and effective in rat and mouse models for treating chemotherapy- and radiation-induced oral mucositis, demonstrating improved tissue regeneration and healing, most notably at higher concentrations.

In this study, researchers found no significant differences in the serum levels of DHEAs, DHT, and testosterone between female patients with oral lichen planus and healthy controls, suggesting no neuroendocrine etiology is associated with this condition.

In this case report, Triamcinolone Acetonide injections effectively improved mouth opening in patients with Oral Submucous Fibrosis, but both developed symptoms of Cushing's Syndrome, prompting the need for careful monitoring due to potential adverse effects when using this treatment.

This review discusses the developmental plasticity between teeth and taste buds in cichlid fishes and reports no new experimental findings, highlighting potential implications for craniofacial organ patterning and regeneration.

This systematic review concluded that the support for using spironolactone at commonly prescribed doses is based on evidence of limited quality.

This study observed that low-dose oral minoxidil and topical minoxidil 5% solution both improved hair density in women with female-pattern hair loss, but oral minoxidil may offer advantages in reducing hair shedding.

In this retrospective analysis, combination therapy with tofacitinib and oral minoxidil led to significant scalp hair regrowth in patients with severe alopecia areata, with 67% achieving at least 75% regrowth, although the small sample size limits the findings.

This case series reports the experience of using oral minoxidil at 1.25 mg/day in 32 patients with male androgenetic alopecia, noting both therapeutic effects and potential adverse reactions.